Moleculin Biotech, Inc. (MBRX) Earnings Call Transcript & Summary

Hi. I'm Wally Klemp, Co-Founder, Chairman and Chief Executive Officer of Moleculin Biotech, Inc. Following the adjournment last week of our 2023 Annual General Meeting, I wanted to take a moment to connect with our stockholders on a very important topic prior to the June 15 AGM adjournment date. We believe that 2022 was a year of fundamental clinical and regulatory execution and it positioned Moleculin to generate important clinical data readouts throughout 2023. In fact, we're calling this our year of data. Now it took a long time to get to this point. But now that we're finally here, we need to take every precaution to ensure our shareholders are in the best possible position when this data starts to roll in. The Moleculin Board and management strongly believe that our NASDAQ listing will be extremely valuable and, in fact, critical to our success through our year of data as well as through our next phase of growth as we work to bring annamycin closer to potential approval and commercialization. I do want to assure you that we have been listening to investor feedback and have closed the voting on Proposal 6 for the authorized share increase and it has not been approved. However, we are strongly encouraging shareholders to vote for the reverse stock split enabled by Proposal 5. This approval will provide Moleculin's management and Board the ability to implement at our careful and thoughtful discretion if we're unable to meet the NASDAQ listing criteria. In closing, I'd like to stress that our growing pipeline is positioned to generate important clinical data readouts throughout 2023. We believe this progress positions us for several value inflection points as this expected news flow unfolds. And importantly, we believe we have the balance sheet we need to reach several critical clinical development milestones that are designed to drive significant shareholder value. We have never been more excited for or confident in the future of Moleculin. Please help us ensure that future. Thank you for your time and consideration. By the way, if you need assistance in voting your shares, please call our proxy solicitor, Okapi Partners, at 844-343-2643. Thank you.